RxDoctor Payments Data

Fernando Mendoza, MD

Cardiovascular Disease · Los Alamitos, CANPI 1063637320

Payments from drug & device makers

$168,792in general payments, 2019–2025

Across 1,030 payments — averaging $163.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$114K
  • Janssen Research & Development, LLC$39K
  • Abbott$2K
  • Novartis$2K
  • Boehringer Ingelheim$1K
  • Novo Nordisk$1K
  • plus $10K from 51 others

What the payments were for

  • Consulting fees$1250%
  • Speaking & faculty fees$101,21178%
  • Travel & lodging$9,0207%
  • Food & beverage$19,86615%
  • Education$670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$168,792 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$1,597,044
Medicare patients
1,128
Services billed
23,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis19$896,269
EliquisApixaban417$479,329
XareltoRivaroxaban215$276,081
JardianceEmpagliflozin176$252,021
Repatha SureclickEvolocumab125$130,261
FarxigaDapagliflozin Propanediol77$109,697
OzempicSemaglutide52$88,548
Praluent PenAlirocumab57$67,554
Metformin Er GastricMetformin Hcl11$40,572
MultaqDronedarone Hcl18$38,400
VascepaIcosapent Ethyl80$18,865
EntrestoSacubitril/Valsartan17$18,196
TrulicityDulaglutide13$12,220
Nebivolol Hcl76$8,852
Icosapent Ethyl24$8,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$113,511$1,375,597436 claims
Johnson & JohnsonXarelto$879$276,081215 claims
Boehringer IngelheimJardiance$1,190$252,021176 claims
AstraZenecaFarxiga$651$109,69777 claims
Novo NordiskOzempic$1,121$88,54852 claims
Sanofi-aventis U.S. LLCMultaq$861$38,40018 claims
NovartisEntresto$2,071$18,19617 claims
Lilly USA, LLCTrulicity$193$12,22013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Los Alamitos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →